Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ) (XVIPY) Stock Competitors & Peer Comparison
See (XVIPY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XVIPY | $6.54 | +0.00% | 206M | N/A | N/A | N/A |
| BMXXY | $12.44 | +2.73% | 14.7B | 31.90 | $0.39 | +0.79% |
| EBOSY | $23.80 | -1.24% | 1.2B | 16.64 | $1.43 | +4.74% |
| AVNBF | $24.70 | +0.00% | 724M | 72.65 | $0.34 | +0.99% |
| EBRCZ | $0.48 | +0.00% | 355.3M | -3.97 | -$0.12 | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| ACIXF | $0.03 | +0.00% | 32.6M | -2.90 | -$0.01 | N/A |
| NVNBW | $0.01 | +0.00% | 141.5K | -0.00 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | +0.00% | 38.1K | -0.01 | -$0.01 | N/A |
Stock Comparison
XVIPY vs BMXXY Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, BMXXY has a market cap of 14.7B. Regarding current trading prices, XVIPY is priced at $6.54, while BMXXY trades at $12.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 31.90. In terms of profitability, XVIPY's ROE is +0.05%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, XVIPY is less volatile compared to BMXXY. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check BMXXY's competition here
XVIPY vs EBOSY Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, EBOSY has a market cap of 1.2B. Regarding current trading prices, XVIPY is priced at $6.54, while EBOSY trades at $23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 16.64. In terms of profitability, XVIPY's ROE is +0.05%, compared to EBOSY's ROE of +0.06%. Regarding short-term risk, XVIPY is less volatile compared to EBOSY. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check EBOSY's competition here
XVIPY vs AVNBF Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, AVNBF has a market cap of 724M. Regarding current trading prices, XVIPY is priced at $6.54, while AVNBF trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas AVNBF's P/E ratio is 72.65. In terms of profitability, XVIPY's ROE is +0.05%, compared to AVNBF's ROE of +0.05%. Regarding short-term risk, XVIPY is less volatile compared to AVNBF. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check AVNBF's competition here
XVIPY vs EBRCZ Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, EBRCZ has a market cap of 355.3M. Regarding current trading prices, XVIPY is priced at $6.54, while EBRCZ trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -3.97. In terms of profitability, XVIPY's ROE is +0.05%, compared to EBRCZ's ROE of -329.75%. Regarding short-term risk, XVIPY and EBRCZ have similar daily volatility (0.00).Check EBRCZ's competition here
XVIPY vs TRXDW Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, XVIPY is priced at $6.54, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to TRXDW's ROE of -1.18%. Regarding short-term risk, XVIPY and TRXDW have similar daily volatility (0.00).Check TRXDW's competition here
XVIPY vs ACIXF Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, ACIXF has a market cap of 32.6M. Regarding current trading prices, XVIPY is priced at $6.54, while ACIXF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas ACIXF's P/E ratio is -2.90. In terms of profitability, XVIPY's ROE is +0.05%, compared to ACIXF's ROE of -1.04%. Regarding short-term risk, XVIPY and ACIXF have similar daily volatility (0.00).Check ACIXF's competition here
XVIPY vs NVNBW Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, NVNBW has a market cap of 141.5K. Regarding current trading prices, XVIPY is priced at $6.54, while NVNBW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.00. In terms of profitability, XVIPY's ROE is +0.05%, compared to NVNBW's ROE of -0.61%. Regarding short-term risk, XVIPY is less volatile compared to NVNBW. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check NVNBW's competition here
XVIPY vs GWPC Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, XVIPY is priced at $6.54, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, XVIPY's ROE is +0.05%, compared to GWPC's ROE of N/A. Regarding short-term risk, XVIPY and GWPC have similar daily volatility (0.00).Check GWPC's competition here
XVIPY vs SXHHF Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, XVIPY is priced at $6.54, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, XVIPY's ROE is +0.05%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, XVIPY is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check SXHHF's competition here
XVIPY vs DGCRF Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, XVIPY is priced at $6.54, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, XVIPY's ROE is +0.05%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, XVIPY is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check DGCRF's competition here
XVIPY vs KKUR Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, XVIPY is priced at $6.54, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to KKUR's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to KKUR. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check KKUR's competition here
XVIPY vs SCIE Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, XVIPY is priced at $6.54, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is -0.00. In terms of profitability, XVIPY's ROE is +0.05%, compared to SCIE's ROE of +0.51%. Regarding short-term risk, XVIPY and SCIE have similar daily volatility (0.00).Check SCIE's competition here
XVIPY vs OMRX Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, OMRX has a market cap of 4.7K. Regarding current trading prices, XVIPY is priced at $6.54, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, XVIPY is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check OMRX's competition here
XVIPY vs IBXG Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, XVIPY is priced at $6.54, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to IBXG's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to IBXG. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check IBXG's competition here
XVIPY vs DMSI Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, XVIPY is priced at $6.54, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, XVIPY is less volatile compared to DMSI. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check DMSI's competition here
XVIPY vs AAXT Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, XVIPY is priced at $6.54, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, XVIPY and AAXT have similar daily volatility (0.00).Check AAXT's competition here
XVIPY vs XCRP Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, XCRP has a market cap of 1.5K. Regarding current trading prices, XVIPY is priced at $6.54, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas XCRP's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, XVIPY and XCRP have similar daily volatility (0.00).Check XCRP's competition here
XVIPY vs BMGP Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, XVIPY is priced at $6.54, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, XVIPY is less volatile compared to BMGP. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check BMGP's competition here
XVIPY vs IMRSQ Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, XVIPY is priced at $6.54, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, XVIPY is less volatile compared to IMRSQ. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check IMRSQ's competition here
XVIPY vs STBV Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, STBV has a market cap of 471. Regarding current trading prices, XVIPY is priced at $6.54, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas STBV's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to STBV's ROE of -1.13%. Regarding short-term risk, XVIPY is less volatile compared to STBV. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check STBV's competition here
XVIPY vs OMDD Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, OMDD has a market cap of 310. Regarding current trading prices, XVIPY is priced at $6.54, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.05%, compared to OMDD's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to OMDD. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.Check OMDD's competition here
XVIPY vs QMED Comparison April 2026
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 206M. In comparison, QMED has a market cap of 17. Regarding current trading prices, XVIPY is priced at $6.54, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, XVIPY's ROE is +0.05%, compared to QMED's ROE of N/A. Regarding short-term risk, XVIPY and QMED have similar daily volatility (0.00).Check QMED's competition here